Who Gets Credit for Medical Discovery?

At the University of Toronto, Frederick Banting pursued an idea about pancreatic extracts with medical student Charles Best in John Macleod's laboratory. Macleod supplied space, animals, guidance, and an established physiological setting. Biochemist James Collip then made crucial progress in purification as the group moved toward treating patients.

The 1923 Nobel Prize went to Banting and Macleod. Banting, angered that Best was excluded, shared his prize money with him; Macleod shared his portion with Collip. The dispute shows why credit cannot be solved merely by adding names. The participants disagreed about the relative importance of the initiating idea, laboratory labour, supervision, biochemical skill, and the authority that secured rapid recognition.

Insulin also required clinical care, access to animal pancreases, production at Connaught Laboratories and through pharmaceutical partners, quality control, patents, and distribution. The University of Toronto became a central actor because it coordinated knowledge and ownership. A therapy emerged from an institutional system, not only from a successful experiment.

In 1928, Alexander Fleming investigated the antibacterial effect associated with mould contaminating a culture plate. He isolated the mould, named penicillin, and published the observation. The surviving plate story is powerful because a clear zone seems to make discovery visible at a glance.

Yet Fleming could not stabilise and purify penicillin as a therapy. A decade later, Howard Florey, Ernst Chain, Norman Heatley, and a wider Oxford group developed extraction, experimental testing, and early treatment. Wartime agencies, chemical engineers, fermentation specialists, pharmaceutical companies, laboratory workers, and clinicians then helped make production possible at scale.

The 1945 Nobel Prize recognised Fleming, Chain, and Florey. That allocation captured three important roles but not the whole system. Fleming himself stressed that he had found a clue and that an organised team was necessary to bring it to therapeutic use. The heroic accident survives because it offers a cleaner beginning than the industrial history that followed.

Scientific papers have author lists but may hide technicians, participants, or institutional support. Patents reward legally defined invention, not every form of discovery or care. Prizes usually recognise a small number of living individuals. Museums select objects that can stand for events, while anniversaries favour stories with a clear date and protagonist.

Power affects visibility at every stage. Senior researchers may control publication; metropolitan laboratories may receive credit for knowledge or specimens gathered elsewhere; women and racialised researchers may have less access to posts that convert labour into authorship; patients and experimental subjects may appear only as data. National competition can turn multinational systems into patriotic achievements.

The solution is not to abolish individual biography. People make consequential decisions, and responsibility matters. The better approach is to specify the contribution being credited: proposing, observing, proving, purifying, organising, manufacturing, caring, funding, or implementing. Precision produces a richer and more defensible history.

Discovery stories teach audiences what science is supposed to look like. The lone observer rewards attentiveness; the inspired hypothesis rewards originality; the decisive experiment rewards method. Each model contains truth, but none explains how a treatment becomes reliable, affordable, and widely available.

Asking who gets credit therefore opens a larger question: which parts of medicine does society value enough to remember? When histories include purification, maintenance, nursing, manufacturing, community trust, and distribution, discovery becomes less miraculous but more intelligible. It also becomes possible to see where collective achievement created collective obligations.